$4650 | Single User
$5650 | Multi User
$7150 | Corporate License
$9000 | Enterprise License

Human Insulin Market - Drugs (Biologics, Biosimilars), Type (Short Acting, Long Acting, Premixed), Brands (Lantus, NovoRapid, Humalog), Delivery Devices (Pens, Pen Needles, Syringes), Applications (Type 1 Diabetes, Type 2 Diabetes) - Forecasts to 2020
[Lowest Price Guaranteed: $4,650]

Published by MarketsandMarkets: 04 Jan 2016 | 20034 | In Stock
Related Topics: Lantus , Lilly

Introduction

The global human insulin market is poised to reach ~USD 39.13 billion by 2020 growing at a CAGR of 8.1% from 2015 to 2020. North America is expected to hold the largest share of the global human insulin market in 2015. Market growth of human insulin products is being propelled by growing diabetes patient population, increasing population exposure to key risk factors leading to diabetes, rising market demand for human insulin analogs, technological advancements in the field of human insulin delivery devices, and favorable medical reimbursements. However, stringent regulatory requirements for product approval are restraining the growth of human insulin market. In addition, high product manufacturing costs is posing significant challenges for market growth during the forecast period.


In this report, the global human insulin market is segmented on the basis of basis of products (human insulin biologics, insulin analogs & biosimilars, and delivery devices), drug type (rapid-acting, intermediate-acting, long-acting, short-acting, and premixed), drug brand (Lantus, NovoRapid/Novolog, Humalog, Humulin, Insuman, Actrapid, Insulatard, Mixtard, and Other Biosimilar Brands), delivery devices [insulin pens (reusable & disposable), pen needles (standard & safety), and conventional syringes], and applications (type I diabetes & type II diabetes).

Human insulin drugs segment is expected to account for the larger share of the global human insulin market in 2015, followed by insulin delivery devices. Significant demand growth for human insulin drugs during the next five years is owing to factors such as increasing market accessibility of generic human insulin products worldwide, rising government initiatives to support the development and commercialization of effective biosimilars, growing R&D for drug discovery & development, and rising proportion of aging population in developed countries.

Geographically, North America (comprising the U.S. and Canada) is expected to command the largest share of the global human insulin market in 2015, followed by Europe. Asia-Pacific is also poised to grow at the highest CAGR during the forecast period, owing to factors such as growing diabetes prevalence in APAC (coupled with large diabetic & pre-diabetic patient population), strengthening distribution networks of global product manufacturers in the region, evolving regulatory framework for marketing approvals & medical reimbursements, and rising public awareness related to benefits offered by human insulin in diabetes treatment (as compared to anti-diabetic drugs & animal derived insulin).

The global human insulin market is highly competitive, with various global as well as local players. In 2014, the global human insulin devices market was dominated by Sanofi (France), Novo Nordisk A/S (Denmark), and Eli Lilly and Company (U.S.), which together accounted for ~89.0% of the human insulin market. Geographic expansion, new product launches, agreements, collaborations, partnerships, awareness campaigns, and offering research fund & grants are the major strategies adopted by most market players to achieve growth in the global human insulin market.

Reasons to Buy the Report:

From an insight perspective, this research report has focused on various levels of analysis such as market share analysis of the top ten players and company profiles, which together comprise and discuss the basic views on the competitive landscape, emerging and high-growth segments of the human insulin market, and high-growth regions and their respective drivers, restraints, challenges, and opportunities.

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn help firms to garner higher market share. Firms purchasing the report could use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

• Market Penetration: Comprehensive information on the human insulin products offered by the top 10 players in the global market. The report analyzes the human insulin market by product, drug type, drug brand, delivery devices, and applications across key geographic regions

• Product Development/Innovation: Detailed insights on upcoming human insulin products, product pipeline, research and development activities, and new product launches in the market

• Market Development: Comprehensive information on lucrative emerging markets. The report analyzes the markets for various human insulin products across key geographic regions

• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the global human insulin market

• Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of leading players in the global human insulin market

Table of Contents
for Human Insulin Market - Drugs (Biologics, Biosimilars), Type (Short Acting, Long Acting, Premixed), Brands (Lantus, NovoRapid, Humalog), Delivery Devices (Pens, Pen Needles, Syringes), Applications (Type 1 Diabetes, Type 2 Diabetes) - Forecasts to 2020

  • TABLE OF CONTENTS

    1 INTRODUCTION 17

    1.1 OBJECTIVES OF THE STUDY 17

    1.2 MARKET DEFINITION 17

    1.3 MARKET SCOPE 18

    1.3.1 MARKETS COVERED 18

    1.3.2 YEARS CONSIDERED FOR THE STUDY 18

    1.4 CURRENCY 19

    1.5 LIMITATIONS 19

    1.6 STAKEHOLDERS 19

    2 RESEARCH METHODOLOGY 20

    2.1 RESEARCH DATA 20

    2.1.1 SECONDARY DATA 21

    2.1.1.1 Key data from secondary sources 21

    2.1.2 PRIMARY DATA 21

    2.1.2.1 Key data from primary sources 22

    2.1.2.2 Breakdown of primaries 22

    2.2 MARKET SIZE ESTIMATION 23

    2.2.1 BOTTOM-UP APPROACH 23

    2.2.2 TOP-DOWN APPROACH 24

    2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 25

    2.4 RESEARCH ASSUMPTIONS 26

    2.4.1 ASSUMPTIONS 26

    3 EXECUTIVE SUMMARY 27

    3.1 INTRODUCTION 27

    3.2 CURRENT MARKET SCENARIO 27

    3.3 FUTURE OUTLOOK 28

    3.4 CONCLUSION 31

    4 PREMIUM INSIGHTS 32

    4.1 GLOBAL HUMAN INSULIN MARKET (2015–2020) 32

    4.2 GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY TYPE (2015) 33

    4.3 GLOBAL HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY TYPE (2015-2020) 34

    4.4 GLOBAL HUMAN INSULIN DRUGS MARKET, BY BRAND (2015 VS. 2020) 34

    4.5 GLOBAL HUMAN INSULIN PRODUCTS MARKET SIZE, BY COUNTRY (2015-2020) 35

    5 MARKET OVERVIEW 36

    5.1 INTRODUCTION 37

    5.2 MARKET SEGMENTATION 37

    5.3 MARKET EVOLUTION 38

    5.4 MARKET DYNAMICS 39

    5.4.1 KEY MARKET DRIVERS 40

    5.4.1.1 Growth in the number of diabetic patients 40

    5.4.1.2 Rising market demand for human insulin analogs 41

    5.4.1.3 Technological advancements in human insulin delivery devices 42

    5.4.1.4 Favorable medical reimbursement scenario in developed countries 43

    5.4.2 KEY MARKET RESTRAINTS 43

    5.4.2.1 Stringent regulatory requirements for product approval 43

    5.4.3 KEY MARKET OPPORTUNITIES 44

    5.4.3.1 Expansion of healthcare infrastructure across Emerging markets 44

    5.4.3.2 Expected patent expiry of key human insulin drugs 45

    5.4.4 KEY MARKET CHALLENGE 45

    5.4.4.1 High product manufacturing costs 45

    6 INDUSTRY INSIGHTS 47

    6.1 INTRODUCTION 48

    6.2 INDUSTRY TRENDS 48

    6.2.1 GROWING MARKET DEMAND FOR HUMAN INSULIN PENS 48

    6.2.2 INCREASING MARKET FOCUS ON THE PIPELINE DEVELOPMENT OF NOVEL HUMAN INSULIN THERAPIES 49

    6.3 PIPELINE ANALYSIS 51

    6.3.1 BY COMPANY 51

    6.3.2 BY CLINICAL TRIAL PHASE 52

    6.3.3 PORTER’S FIVE FORCE ANALYSIS 53

    6.3.3.1 Threat from new entrants 54

    6.3.3.2 Threat from substitutes 54

    6.3.3.3 Bargaining power of buyers 54

    6.3.3.4 Bargaining power of suppliers 55

    6.3.3.5 Intensity of competitive rivalry 55

    7 GLOBAL HUMAN INSULIN MARKET, BY PRODUCT TYPE 56

    7.1 INTRODUCTION 57

    7.2 HUMAN INSULIN DRUGS 58

    7.3 HUMAN INSULIN DELIVERY DEVICES 59

    8 GLOBAL HUMAN INSULIN DRUGS MARKET, BY TYPE 61

    8.1 INTRODUCTION 62

    8.2 INSULIN ANALOGS AND BIOSIMILARS 62

    8.2.1 LONG-ACTING 64

    8.2.2 RAPID-ACTING 66

    8.2.3 PREMIXED 67

    8.3 HUMAN INSULIN BIOLOGICS 68

    8.3.1 SHORT-ACTING 70

    8.3.2 INTERMEDIATE-ACTING 71

    8.3.3 PREMIXED 72

    9 GLOBAL HUMAN INSULIN DRUGS MARKET, BY BRAND 73

    9.1 INTRODUCTION 74

    9.2 INSULIN ANALOGS AND BIOSIMILARS 75

    9.2.1 LANTUS 77

    9.2.2 NOVORAPID AND NOVOLOG 78

    9.2.3 HUMALOG 79

    9.2.4 OTHER BRANDS 80

    9.3 HUMAN INSULIN BIOLOGICS 81

    9.3.1 ACTRAPID, MIXTARD, AND INSULATARD 83

    9.3.2 HUMULIN 84

    9.3.3 INSUMAN 85

    10 GLOBAL HUMAN INSULIN MARKET, BY DELIVERY DEVICE 86

    10.1 INTRODUCTION 87

    10.2 HUMAN INSULIN PENS 88

    10.2.1 REUSABLE PENS 89

    10.2.2 DISPOSABLE PENS 90

    10.3 HUMAN INSULIN PEN NEEDLES 91

    10.3.1 STANDARD PEN NEEDLES 92

    10.3.2 SAFETY PEN NEEDLES 93

    10.4 HUMAN INSULIN SYRINGES 94

    11 GLOBAL HUMAN INSULIN MARKET, BY APPLICATION 95

    11.1 INTRODUCTION 96

    11.2 TYPE I DIABETES 96

    11.3 TYPE II DIABETES 97

    12 HUMAN INSULIN MARKET, BY REGION 98

    12.1 INTRODUCTION 99

    12.2 NORTH AMERICA 100

    12.2.1 U.S. 103

    12.2.2 CANADA 104

    12.3 EUROPE 106

    12.3.1 GERMANY 109

    12.3.2 FRANCE 110

    12.3.3 U.K. 112

    12.3.4 REST OF EUROPE (ROE) 113

    12.4 ASIA-PACIFIC (APAC) 115

    12.4.1 JAPAN 118

    12.4.2 CHINA 119

    12.4.3 INDIA 120

    12.4.4 REST OF ASIA-PACIFIC (ROAPAC) 122

    12.5 REST OF THE WORLD (ROW) 124

    13 COMPETITIVE LANDSCAPE 126

    13.1 OVERVIEW 126

    13.2 MARKET SHARE ANALYSIS 127

    13.2.1 HUMAN INSULIN DRUGS MARKET 129

    13.2.2 HUMAN INSULIN DELIVERY DEVICES MARKET 130

    13.3 COMPETITIVE SCENARIO 131

    13.4 RECENT DEVELOPMENTS 132

    13.4.1 GEOGRAPHICAL EXPANSIONS 132

    13.4.2 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS 133

    13.4.3 NEW PRODUCT LAUNCHES 134

    13.4.4 AWARENESS PROGRAMS 136

    13.4.5 FUNDING & SCHOLARSHIPS 137

    13.4.6 STRATEGIC ACQUISITIONS 138

    14 COMPANY PROFILES 139

    (Overview, Financials, Products & Services, Strategy, & Developments)*

    14.1 INTRODUCTION 139

    14.2 B. BRAUN MELSUNGEN AG 143

    14.3 BECTON, DICKINSON AND COMPANY 145

    14.4 BIOCON LIMITED 148

    14.5 BIODEL INC. 151

    14.6 ELI LILLY AND COMPANY 152

    14.7 JULPHAR (ALSO KNOWN AS GULF PHARMACEUTICAL INDUSTRIES) 158

    14.8 NOVO NORDISK A/S 160

    14.9 SANOFI 166

    14.10 WOCKHARDT LIMITED 170

    14.11 YPSOMED AG 172

    *Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.

    15 APPENDIX 175

    15.1 INSIGHTS OF INDUSTRY EXPERTS 175

    15.2 DISCUSSION GUIDE 176

    15.3 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 181

    15.4 AVAILABLE CUSTOMIZATIONS 181

    15.5 RELATED REPORTS 182

List Of Tables
in Human Insulin Market - Drugs (Biologics, Biosimilars), Type (Short Acting, Long Acting, Premixed), Brands (Lantus, NovoRapid, Humalog), Delivery Devices (Pens, Pen Needles, Syringes), Applications (Type 1 Diabetes, Type 2 Diabetes) - Forecasts to 2020

LIST OF TABLES


TABLE 1 KEY HUMAN INSULIN DRUGS: YEAR OF PATENT EXPIRY 38

TABLE 2 KEY HUMAN INSULIN THERAPIES UNDER PIPELINE DEVELOPMENT & COMMERCIALIZATION: 2005-2015 50

TABLE 3 HUMAN INSULIN PIPELINE: MAJOR COMPANIES INVOLVED 51

TABLE 4 HUMAN INSULIN PIPELINE: STAGES OF CLINICAL TRIAL 52

TABLE 5 GLOBAL HUMAN INSULIN MARKET SIZE, BY PRODUCT TYPE,

2013–2020 (USD MILLION) 57

TABLE 6 HUMAN INSULIN DRUGS MARKET SIZE, BY REGION, 2013–2020 (USD MILLION) 59

TABLE 7 HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY REGION,

2013–2020 (USD MILLION) 60

TABLE 8 GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY TYPE,

2013–2020 (USD MILLION) 62

TABLE 9 GLOBAL INSULIN ANALOGS AND BIOSIMILARS MARKET SIZE, BY TYPE,

2013–2020 (USD MILLION) 63

TABLE 10 INSULIN ANALOGS AND BIOSIMILARS MARKET SIZE, BY REGION,

2013–2020 (USD MILLION) 64

TABLE 11 LONG-ACTING INSULIN ANALOGS AND BIOSIMILARS MARKET SIZE,

BY REGION, 2013–2020 (USD MILLION) 65

TABLE 12 RAPID-ACTING INSULIN ANALOGS AND BIOSIMILARS MARKET SIZE,

BY REGION, 2013–2020 (USD MILLION) 66

TABLE 13 PREMIXED INSULIN ANALOGS AND BIOSIMILARS MARKET SIZE,

BY REGION, 2013–2020 (USD MILLION) 67

TABLE 14 GLOBAL HUMAN INSULIN BIOLOGICS MARKET SIZE, BY TYPE,

2013–2020 (USD MILLION) 68

TABLE 15 HUMAN INSULIN BIOLOGICS MARKET SIZE, BY REGION,

2013–2020 (USD MILLION) 69

TABLE 16 SHORT-ACTING HUMAN INSULIN BIOLOGICS MARKET SIZE, BY REGION,

2013–2020 (USD MILLION) 70

TABLE 17 INTERMEDIATE-ACTING HUMAN INSULIN BIOLOGICS MARKET SIZE,

BY REGION, 2013–2020 (USD MILLION) 71

TABLE 18 PREMIXED HUMAN INSULIN BIOLOGICS MARKET SIZE, BY REGION,

2013–2020 (USD MILLION) 72

TABLE 19 GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY PRODUCT TYPE,

2013–2020 (USD MILLION) 74

TABLE 20 GLOBAL INSULIN ANALOGS AND BIOSIMILARS MARKET SIZE, BY BRAND,

2013–2020 (USD MILLION) 75

TABLE 21 INSULIN ANALOGS AND BIOSIMILARS MARKET SIZE, BY REGION,

2013–2020 (USD MILLION) 76

TABLE 22 INSULIN ANALOGS AND BIOSIMILARS MARKET SIZE FOR LANTUS,

BY REGION, 2013–2020 (USD MILLION) 77

TABLE 23 INSULIN ANALOGS AND BIOSIMILARS MARKET SIZE FOR NOVORAPID AND NOVOLOG, BY REGION, 2013–2020 (USD MILLION) 78

TABLE 24 INSULIN ANALOGS AND BIOSIMILARS MARKET SIZE FOR HUMALOG,

BY REGION, 2013–2020 (USD MILLION) 80

TABLE 25 INSULIN ANALOGS AND BIOSIMILARS MARKET SIZE FOR OTHER BRANDS,

BY REGION, 2013–2020 (USD MILLION) 81

TABLE 26 GLOBAL HUMAN INSULIN BIOLOGICS MARKET SIZE, BY BRAND,

2013–2020 (USD MILLION) 81

TABLE 27 HUMAN INSULIN BIOLOGICS MARKET SIZE, BY REGION,

2013–2020 (USD MILLION) 82

TABLE 28 HUMAN INSULIN BIOLOGICS MARKET SIZE FOR ACTRAPID, MIXTARD, AND INSULATARD, BY REGION, 2013–2020 (USD MILLION) 83

TABLE 29 HUMAN INSULIN BIOLOGICS MARKET SIZE FOR HUMULIN, BY REGION,

2013–2020 (USD MILLION) 84

TABLE 30 HUMAN INSULIN BIOLOGICS MARKET SIZE FOR INSUMAN, BY REGION,

2013–2020 (USD MILLION) 85

TABLE 31 GLOBAL HUMAN INSULIN MARKET SIZE, BY DELIVERY DEVICE,

2013–2020 (USD MILLION) 87

TABLE 32 GLOBAL HUMAN INSULIN PENS MARKET SIZE, BY PRODUCT TYPE,

2013–2020 (USD MILLION) 88

TABLE 33 HUMAN INSULIN PENS MARKET SIZE, BY REGION, 2013–2020 (USD MILLION) 88

TABLE 34 REUSABLE HUMAN INSULIN PENS MARKET SIZE, BY REGION,

2013–2020 (USD MILLION) 89

TABLE 35 DISPOSABLE HUMAN INSULIN PENS MARKET SIZE, BY REGION,

2013–2020 (USD MILLION) 90

TABLE 36 GLOBAL HUMAN INSULIN PEN NEEDLES MARKET SIZE, BY PRODUCT TYPE,

2013–2020 (USD MILLION) 91

TABLE 37 HUMAN INSULIN PEN NEEDLES MARKET SIZE, BY REGION,

2013–2020 (USD MILLION) 92

TABLE 38 HUMAN INSULIN STANDARD PEN NEEDLES MARKET SIZE, BY REGION,

2013–2020 (USD MILLION) 93

TABLE 39 HUMAN INSULIN SAFETY PEN NEEDLES MARKET SIZE, BY REGION,

2013–2020 (USD MILLION) 94

TABLE 40 HUMAN INSULIN SYRINGES MARKET SIZE, BY REGION,

2013–2020 (USD MILLION) 94

TABLE 41 HUMAN INSULIN MARKET SIZE, BY REGION, 2013–2020 (USD MILLION) 99

TABLE 42 NORTH AMERICA: HUMAN INSULIN MARKET SIZE, BY COUNTRY,

2013–2020 (USD MILLION) 100

TABLE 43 NORTH AMERICA: HUMAN INSULIN MARKET SIZE, BY PRODUCT,

2013–2020 (USD MILLION) 100

TABLE 44 NORTH AMERICA: HUMAN INSULIN DRUGS MARKET SIZE, BY PRODUCT,

2013–2020 (USD MILLION) 101

TABLE 45 NORTH AMERICA: HUMAN INSULIN DELIVERY DEVICES MARKET SIZE,

BY PRODUCT, 2013–2020 (USD MILLION) 101

TABLE 46 U.S.: HUMAN INSULIN MARKET SIZE, BY PRODUCT, 2013–2020 (USD MILLION) 103

TABLE 47 U.S.: HUMAN INSULIN DRUGS MARKET SIZE, BY PRODUCT,

2013–2020 (USD MILLION) 104

TABLE 48 U.S.: HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY PRODUCT,

2013–2020 (USD MILLION) 104

TABLE 49 CANADA: HUMAN INSULIN MARKET SIZE, BY PRODUCT,

2013–2020 (USD MILLION) 105

TABLE 50 CANADA: HUMAN INSULIN DRUGS MARKET SIZE, BY PRODUCT,

2013–2020 (USD MILLION) 105

TABLE 51 CANADA: HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY PRODUCT,

2013–2020 (USD MILLION) 105

TABLE 52 EUROPE: HUMAN INSULIN MARKET SIZE, BY COUNTRY,

2013–2020 (USD MILLION) 106

TABLE 53 EUROPE: HUMAN INSULIN MARKET SIZE, BY PRODUCT,

2013–2020 (USD MILLION) 106

TABLE 54 EUROPE: HUMAN INSULIN DRUGS MARKET SIZE, BY PRODUCT,

2013–2020 (USD MILLION) 107

TABLE 55 EUROPE: HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY PRODUCT,

2013–2020 (USD MILLION) 107

TABLE 56 GERMANY: HUMAN INSULIN MARKET SIZE, BY PRODUCT,

2013–2020 (USD MILLION) 109

TABLE 57 GERMANY: HUMAN INSULIN DRUGS MARKET SIZE, BY PRODUCT,

2013–2020 (USD MILLION) 109

TABLE 58 GERMANY: HUMAN INSULIN DELIVERY DEVICES MARKET SIZE,

BY PRODUCT, 2013–2020 (USD MILLION) 110

TABLE 59 FRANCE: HUMAN INSULIN MARKET SIZE, BY PRODUCT,

2013–2020 (USD MILLION) 110

TABLE 60 FRANCE: HUMAN INSULIN DRUGS MARKET SIZE, BY PRODUCT,

2013–2020 (USD MILLION) 111

TABLE 61 FRANCE: HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY PRODUCT,

2013–2020 (USD MILLION) 111

TABLE 62 U.K.: HUMAN INSULIN MARKET SIZE, BY PRODUCT, 2013–2020 (USD MILLION) 112

TABLE 63 U.K.: HUMAN INSULIN DRUGS MARKET SIZE, BY PRODUCT,

2013–2020 (USD MILLION) 112

TABLE 64 U.K.: HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY PRODUCT,

2013–2020 (USD MILLION) 113

TABLE 65 ROE: HUMAN INSULIN MARKET SIZE, BY PRODUCT, 2013–2020 (USD MILLION) 113

TABLE 66 ROE: HUMAN INSULIN DRUGS MARKET SIZE, BY PRODUCT,

2013–2020 (USD MILLION) 114

TABLE 67 ROE: HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY PRODUCT,

2013–2020 (USD MILLION) 114

TABLE 68 APAC: HUMAN INSULIN MARKET SIZE, BY COUNTRY, 2013–2020 (USD MILLION) 115

TABLE 69 APAC: HUMAN INSULIN MARKET SIZE, BY PRODUCT, 2013–2020 (USD MILLION) 115

TABLE 70 APAC: HUMAN INSULIN DRUGS MARKET SIZE, BY PRODUCT,

2013–2020 (USD MILLION) 116

TABLE 71 APAC: HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY PRODUCT,

2013–2020 (USD MILLION) 116

TABLE 72 JAPAN: HUMAN INSULIN MARKET SIZE, BY PRODUCT, 2013–2020 (USD MILLION) 118

TABLE 73 JAPAN: HUMAN INSULIN DRUGS MARKET SIZE, BY PRODUCT,

2013–2020 (USD MILLION) 118

TABLE 74 JAPAN: HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY PRODUCT,

2013–2020 (USD MILLION) 119

TABLE 75 CHINA: HUMAN INSULIN MARKET SIZE, BY PRODUCT, 2013–2020 (USD MILLION) 119

TABLE 76 CHINA: HUMAN INSULIN DRUGS MARKET SIZE, BY PRODUCT,

2013–2020 (USD MILLION) 120

TABLE 77 CHINA: HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY PRODUCT,

2013–2020 (USD MILLION) 120

TABLE 78 INDIA: HUMAN INSULIN MARKET SIZE, BY PRODUCT, 2013–2020 (USD MILLION) 121

TABLE 79 INDIA: HUMAN INSULIN DRUGS MARKET SIZE, BY PRODUCT,

2013–2020 (USD MILLION) 121

TABLE 80 INDIA: HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY PRODUCT,

2013–2020 (USD MILLION) 121

TABLE 81 ROAPAC: HUMAN INSULIN MARKET SIZE, BY PRODUCT,

2013–2020 (USD MILLION) 122

TABLE 82 ROAPAC: HUMAN INSULIN DRUGS MARKET SIZE, BY PRODUCT,

2013–2020 (USD MILLION) 123

TABLE 83 ROAPAC: HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY PRODUCT,

2013–2020 (USD MILLION) 123

TABLE 84 ROW: HUMAN INSULIN MARKET SIZE, BY PRODUCT, 2013–2020 (USD MILLION) 124

TABLE 85 ROW: HUMAN INSULIN DRUGS MARKET SIZE, BY PRODUCT,

2013–2020 (USD MILLION) 125

TABLE 86 ROW: HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY PRODUCT,

2013–2020 (USD MILLION) 125

TABLE 87 GEOGRAPHICAL EXPANSIONS, 2012–2015 132

TABLE 88 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS, 2012–2015 133

TABLE 89 NEW PRODUCT LAUNCHES AND PRODUCT APPROVALS, 2012–2015 134

TABLE 90 AWARENESS PROGRAMS, 2012–2015 136

TABLE 91 FUNDING & SCHOLARSHIPS, 2012–2015 137

TABLE 92 STRATEGIC ACQUISITIONS, 2012–2015 138

List Of Figures, Charts and Diagrams
in Human Insulin Market - Drugs (Biologics, Biosimilars), Type (Short Acting, Long Acting, Premixed), Brands (Lantus, NovoRapid, Humalog), Delivery Devices (Pens, Pen Needles, Syringes), Applications (Type 1 Diabetes, Type 2 Diabetes) - Forecasts to 2020

LIST OF FIGURES


FIGURE 1 RESEARCH DESIGN 20

FIGURE 2 BOTTOM-UP APPROACH 23

FIGURE 3 TOP-DOWN APPROACH 24

FIGURE 4 DATA TRIANGULATION 25

FIGURE 5 ASSUMPTIONS FOR THE RESEARCH STUDY 26

FIGURE 6 HUMAN INSULIN MARKET SHARE, BY KEY PLAYER, 2014 27

FIGURE 7 FUTURE TRENDS: HUMAN INSULIN MARKET SIZE, BY PRODUCT (2015–2020) 28

FIGURE 8 FUTURE TRENDS: HUMAN INSULIN DRUGS MARKET SHARE, BY TYPE (2015 VS. 2020) 29

FIGURE 9 FUTURE TRENDS: HUMAN INSULIN DRUGS MARKET SIZE, BY BRAND (2015–2020) 29

FIGURE 10 FUTURE TRENDS: HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE (2015–2020) 30

FIGURE 11 FUTURE TRENDS: HUMAN INSULIN MARKET SHARE, BY REGION (2015) 31

FIGURE 12 ATTRACTIVE GROWTH OPPORTUNITIES IN THE HUMAN INSULIN MARKET 32

FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE HUMAN INSULIN MARKET

IN 2015 33

FIGURE 14 NORTH AMERICA TO COMMAND THE LARGEST SHARE OF ALL SEGMENTS OF THE HUMAN INSULIN DELIVERY DEVICES MARKET IN 2015 34

FIGURE 15 LANTUS IS EXPECTED TO BE THE LEADING INSULIN ANALOG TILL 2020 34

FIGURE 16 CHINA AND INDIA TO LEAD THE MARKET DEMAND FOR HUMAN INSULIN PRODUCTS DURING THE FORECAST PERIOD 35

FIGURE 17 MARKET EVOLUTION OF HUMAN INSULIN PRODUCTS 38

FIGURE 18 HUMAN INSULIN MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, & CHALLENGES 39

FIGURE 19 GROWTH IN DIABETIC PATIENT POPULATION ACROSS KEY WHO REGIONS

(2000–2030) 40

FIGURE 20 PROPORTION OF GERIATRIC POPULATION, BY COUNTRY (2012 VS. 2020) 41

FIGURE 21 GLOBAL TREND IN GOVERNMENT HEALTHCARE EXPENDITURE: DEVELOPED VS. DEVELOPING COUNTRIES (2010–2012) 44

FIGURE 22 PORTER’S FIVE FORCES ANALYSIS (2014): INCREASING NUMBER OF NEW PRODUCT MANUFACTURERS INCREASES MARKET COMPETITION 53

FIGURE 23 DELIVERY DEVICES POISED TO GROW AT THE HIGHEST RATE DURING 2015-2020 57

FIGURE 24 U.S. & EUROPE LEAD GLOBALLY, IN TERMS OF THE NUMBER OF ONGOING HUMAN INSULIN-BASED CLINICAL STUDIES (2015) 58

FIGURE 25 LONG-ACTING DRUGS TO LEAD THE INSULIN ANALOGS AND BIOSIMILARS MARKET TILL 2020 63

FIGURE 26 ASIA-PACIFIC IS POISED TO BE THE FASTEST GROWING MARKET FOR LONG-ACTING INSULIN ANALOGS AND BIOSIMILAR PRODUCTS DURING FORECAST PERIOD 65

FIGURE 27 INTERMEDIATE-ACTING DRUGS WILL CONTINUE TO DOMINATE THE HUMAN INSULIN BIOLOGICS MARKET TILL 2020 69

FIGURE 28 NORTH AMERICA IS EXPECTED TO DOMINATE THE INTERMEDIATE-ACTING HUMAN INSULIN BIOLOGICS MARKET DURING THE STUDY PERIOD 71

FIGURE 29 INSULIN ANALOGS & BIOSIMILAR DRUGS POISED TO GROW AT THE FASTEST RATE 75

FIGURE 30 LANTUS EXPECTED TO HOLD THE LARGEST SHARE OF INSULIN ANALOGS & BIOSIMILAR BRANDS MARKET TILL 2020 76

FIGURE 31 ASIA-PACIFIC POISED TO BE THE FASTEST-GROWING MARKET FOR NOVORAPID DURING THE FORECAST PERIOD 79

FIGURE 32 HUMULIN IS POISED TO BE THE FASTEST-GROWING HUMAN INSULIN BIOLOGICS BRANDS DURING 2015-2020 82

FIGURE 33 INSULIN PENS TO DOMINATE THE HUMAN INSULIN DELIVERY DEVICES MARKET DURING THE FORECAST PERIOD (2015–2020) 87

FIGURE 34 APAC TO DOMINATE THE HUMAN INSULIN PEN NEEDLES MARKET BY 2020 91

FIGURE 35 INDIA WILL HAVE THE HIGHEST DIABETES POPULATION BY 2030 97

FIGURE 36 MARKET TRENDS: NORTH AMERICAN HUMAN INSULIN MARKET (2015-2020) 102

FIGURE 37 MARKET TRENDS: EUROPEAN HUMAN INSULIN MARKET (2015-2020) 108

FIGURE 38 ASIA-PACIFIC HUMAN INSULIN MARKET SNAPSHOT, 2015-2020 117

FIGURE 39 LEADING PLAYERS ADOPTED THE STRATEGY OF GEOGRAPHIC EXPANSIONS TO STRENGTHEN THEIR MARKET POSITIONING DURING 2012 TO 2015 126

FIGURE 40 GLOBAL HUMAN INSULIN MARKET SHARE, BY KEY PLAYER (2014) 127

FIGURE 41 GLOBAL HUMAN INSULIN DRUGS MARKET RANKING, BY KEY PLAYER (2014) 129

FIGURE 42 GLOBAL HUMAN INSULIN DELIVERY DEVICES MARKET RANKING, BY KEY PLAYER (2014) 130

FIGURE 43 CONTINUOUS GEOGRAPHIC EXPANSION IS STIMULATING MARKET COMPETITION FOR CAPACITY BUILDING AMONG KEY PLAYERS 131

FIGURE 44 GEOGRAPHIC REVENUE MIX OF THE TOP 5 MARKET PLAYERS* (2014) 139

FIGURE 45 LEADING COMPANIES ARE FOCUSING ON CAPACITY BUILDING TO STRENGTHEN THEIR PRODUCT DEVELOPMENT & MANUFACTURING BASE 141

FIGURE 46 LEADING HUMAN INSULIN MANUFACTURERS ARE FOCUSING ON PRODUCT COMMERCIALIZATION TO STRENGTHEN THEIR MARKET POSITION 142

FIGURE 47 B. BRAUN MELSUNGEN AG: COMPANY SNAPSHOT 143

FIGURE 48 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT 145

FIGURE 49 BIOCON LIMITED: COMPANY SNAPSHOT 148

FIGURE 50 ELI LILLY AND COMPANY: COMPANY SNAPSHOT 152

FIGURE 51 JULPHAR: COMPANY SNAPSHOT 158

FIGURE 52 NOVO NORDISK A/S: COMPANY SNAPSHOT 160

FIGURE 53 SANOFI: COMPANY SNAPSHOT 166

FIGURE 54 WOCKHARDT LIMITED: COMPANY SNAPSHOT 170

FIGURE 55 YPSOMED AG: COMPANY SNAPSHOT 172

Additional Details

Publisher

MarketsandMarkets

Publisher Information

Reference

20034 | BT 3981

Number of Pages

183

Report Format

PDF

MarketsandMarkets Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Global Human Papilloma Virus Partnering 2010 to 2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Oct 2016 by Current Partnering USD $1,495 More Info
Human Drugs For Veterinary Use - Current Trends and Future Commercial Prospects for Crossover Drugs
Human Drugs For Veterinary Use - Current Trends and Future Commercial Prospects for Crossover DrugsS...
01 May 2016 by CBR Pharma Insights USD $2,995 More Info
National Human Genome Research Institute - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryNational Human Genome Research Institute (NHGRI) a subsidiary of National Institutes of Healt...
27 Apr 2016 by Global Data USD $250 More Info
National Human Genome Research Institute - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryNational Human Genome Research Institute (NHGRI) a subsidiary of National Institutes of Healt...
14 Mar 2016 by Global Data USD $250 More Info
Human Immunodeficiency Virus (HIV) - US Drug Forecast and Market Analysis to 2023
Human Immunodeficiency Virus (HIV) - US Drug Forecast and Market Analysis to 2023SummaryHuman immuno...
09 Sep 2015 by Global Data USD $4,995 More Info
Human Immunodeficiency Virus (HIV) - Japan Drug Forecast and Market Analysis to 2023
Human Immunodeficiency Virus (HIV) - Japan Drug Forecast and Market Analysis to 2023SummaryHuman imm...
09 Sep 2015 by Global Data USD $4,995 More Info
Human Immunodeficiency Virus (HIV) - 5EU Drug Forecast and Market Analysis to 2023
Human Immunodeficiency Virus (HIV) - 5EU Drug Forecast and Market Analysis to 2023SummaryHuman immun...
09 Sep 2015 by Global Data USD $6,995 More Info
Human Immunodeficiency Virus (HIV) - Brazil Drug Forecast and Market Analysis to 2023
Human Immunodeficiency Virus (HIV) - Brazil Drug Forecast and Market Analysis to 2023SummaryHuman im...
09 Sep 2015 by Global Data USD $4,995 More Info
Human Immunodeficiency Virus (HIV) - China Drug Forecast and Market Analysis to 2023
Human Immunodeficiency Virus (HIV) - China Drug Forecast and Market Analysis to 2023SummaryHuman imm...
09 Sep 2015 by Global Data USD $4,995 More Info
Human Immunodeficiency Virus (HIV) - Current and Future Players
Human Immunodeficiency Virus (HIV) - Current and Future PlayersSummaryGlobalData has released its ph...
09 Sep 2015 by Global Data USD $2,995 More Info

This report is published by MarketsandMarkets

Download Free Report Summary PDF

Human Insulin Market - Drugs (Biologics, Biosimilars), Type (Short Acting, Long Acting, Premixed), Brands (Lantus, NovoRapid, Humalog), Delivery Devices (Pens, Pen Needles, Syringes), Applications (Type 1 Diabetes, Type 2 Diabetes) - Forecasts to 2020 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...